madman
Super Moderator
The guest speakers says it all LOL!
The Obesity Society (TOS) convened a panel of leading experts in obesity medicine, pharmacy, and regulatory law on March 19, 2025, to discuss the growing concerns surrounding the use of compounded GLP-1s for weight management and diabetes treatment. The briefing underscored the critical importance of ensuring patient access to safe, FDA-approved GLP-1 medications.
The briefing occurred on the same day as the FDA’s deadline for compounding companies to cease making tirzepatide, according to the FDA’s latest guidance.
The discussion was moderated by Marc-Andre Cornier, MD, president of The Obesity Society, and featured the following speakers:
Angela Fitch, MD, immediate past president of the Obesity Medicine Association
Robert Popovian, PharmD, founder of Conquest Advisors
Lowell Schiller, JD, former principal associate commissioner for policy at the FDA
The Obesity Society (TOS) convened a panel of leading experts in obesity medicine, pharmacy, and regulatory law on March 19, 2025, to discuss the growing concerns surrounding the use of compounded GLP-1s for weight management and diabetes treatment. The briefing underscored the critical importance of ensuring patient access to safe, FDA-approved GLP-1 medications.
The briefing occurred on the same day as the FDA’s deadline for compounding companies to cease making tirzepatide, according to the FDA’s latest guidance.
The discussion was moderated by Marc-Andre Cornier, MD, president of The Obesity Society, and featured the following speakers:
Angela Fitch, MD, immediate past president of the Obesity Medicine Association
Robert Popovian, PharmD, founder of Conquest Advisors
Lowell Schiller, JD, former principal associate commissioner for policy at the FDA
